CROSS-STANDARD public interest · Home/clinical medical device
China-to-Saudi Arabia Medical Device Compliance Gap Matrix
AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical medical device documentation against Saudi Arabia SFDA Medical Device Marketing Authorization (MDMA), device classification (MDIR Classes A–D), Authorized Representative, ISO 13485 QMS, IEC 60601-1 electromedical safety, clinical evidence, risk management, Arabic labelling, and UDI requirements.
Dataset 2026-06-11
Last verified 2026-06-12
6 rows
GAP MATRIX
Compliance Gap Matrix
| Compliance item | Common China baseline | Saudi Arabia (SFDA) | Gap / action | Source + verification date |
|---|---|---|---|---|
| Authorized Representative — Saudi-Based Mandatory Local Agent | China does not impose an outbound Authorized Representative requirement on Chinese manufacturers exporting medical devices. For devices imported into China, the foreign manufacturer must designate a Chinese legal entity (the filing agent or registration agent — 备案人/注册代理人) to act as the domestic responsible party for NMPA registration. However, this is an inbound requirement for foreign products entering China, not an outbound requirement for Chinese manufacturers entering foreign markets. There is no NMPA requirement mandating that a Chinese exporter appoint a local representative in the destination country.医疗器械注册与备案管理办法 (NMPA Order No. 47, 2021 — inbound import agent requirement) 医疗器械监督管理条例 (State Council Order No. 739, 2021) |
SFDA mandates that all foreign medical device manufacturers appoint a Saudi Arabia-based Authorized Representative (AR) — also referred to as a local agent or local distributor — as a prerequisite for all MDMA applications. The AR must be a Saudi legal entity registered with SFDA. The AR acts on behalf of the foreign manufacturer for all regulatory interactions with SFDA and bears legal responsibility for post-market obligations in the Saudi market, including: receiving and responding to SFDA communications, managing product recalls and field safety corrective actions (FSCAs), submitting vigilance reports, and maintaining the MDMA registration. A foreign manufacturer cannot submit an MDMA application directly without a registered Saudi AR. The AR relationship must be documented by a formal agreement (letter of authorization or distributorship agreement).Royal Decree No. (M/54) 2021 — Law of Medical Devices, Saudi Arabia Medical Devices Interim Regulation (MDIR) 2019 — subordinate implementing regulation SFDA Medical Device Marketing Authorization Procedural Requirements SFDA Authorized Representative / Local Agent Registration Requirements |
There is a complete structural gap: Saudi Arabia mandates a Saudi-based AR for all foreign manufacturer MDMA applications; China has no equivalent outbound requirement. Chinese manufacturers entering the Saudi market must: (1) Identify and contract a Saudi legal entity registered with SFDA to act as AR before submitting any MDMA application. (2) Execute a formal letter of authorization or distributorship agreement recognized by SFDA. (3) Ensure the AR understands and accepts its post-market obligations (recalls, vigilance, MDMA maintenance). (4) Plan for ongoing AR relationship management — the AR must remain active and registered with SFDA for the lifetime of the MDMA registration. Finding a qualified, SFDA-registered Saudi AR is a prerequisite step that can add significant lead time (verify current figures with Saudi trade advisors) to the Saudi market entry timeline.For informational reference only. Appointing a Saudi-based Authorized Representative registered with SFDA is a non-negotiable prerequisite for Chinese manufacturers entering the Saudi medical device market. There is no NMPA-equivalent framework to reference. This is typically one of the earliest steps in the Saudi market entry process and should be initiated well in advance of MDMA filing. Consult a Saudi trade law advisor and a medical device regulatory specialist to identify qualified SFDA-registered AR candidates. | Saudi Food and Drug Authority (SFDA)2026-06-12 · unverified |
| Clinical / Safety Evidence, Risk Management, and Post-Market Surveillance | In China, clinical evaluation is required for Class II and III medical devices under NMPA Order No. 47 (2021) and supporting clinical evaluation guidance. Acceptable approaches include: clinical trial conducted in China, clinical literature evaluation, or recognition of clinical data from foreign approvals (under specific NMPA recognition criteria). Risk management must comply with YY/T 0316 (ISO 14971 equivalent). Post-market surveillance and adverse event reporting are mandatory under State Council Order No. 739. The NMPA clinical evaluation framework is broadly similar in structure to international practice but uses China-specific documentation formats and submission channels.YY/T 0316 (ISO 14971:2019 equivalent — Risk management) 医疗器械临床评价技术指导原则 (NMPA Clinical Evaluation Guidance 2021) 医疗器械不良事件监测和再评价管理办法 (NMPA Order No. 1, 2019 — Vigilance) 医疗器械监督管理条例 (State Council Order No. 739, 2021) |
SFDA requires clinical evidence as part of the MDMA technical dossier for Class B, C, and D devices. Acceptable clinical evidence includes: clinical data from clinical investigations, clinical literature evaluation, post-market clinical data, and data from equivalent devices. For devices on the SFDA Recognition List (already approved by a founding regulator such as US FDA or EU CE), SFDA may accept the clinical data package submitted in the original founding regulator application, reducing the need to generate new clinical data. A risk management file compliant with ISO 14971 (medical devices risk management) is required as part of the technical dossier. A post-market surveillance (PMS) plan must be submitted with the MDMA application. Manufacturers are required to report serious incidents and field safety corrective actions (FSCAs) to SFDA via the vigilance reporting system.ISO 14971:2019 — Medical devices: Application of risk management Royal Decree No. (M/54) 2021 — Law of Medical Devices, Saudi Arabia Medical Devices Interim Regulation (MDIR) 2019 — subordinate implementing regulation SFDA Medical Device Marketing Authorization Technical Dossier Requirements SFDA Vigilance Reporting Guidelines |
The clinical and risk management standards are structurally aligned (ISO 14971 / YY/T 0316; both accept clinical literature evaluation). Key gaps: (1) NMPA clinical evaluation files are formatted for the Chinese regulatory system; SFDA dossiers must be reformatted/restructured to SFDA template requirements. (2) Devices holding only NMPA registration — not a founding regulator approval — cannot use the SFDA recognition/fast-track pathway; full clinical evidence submission is required. (3) Chinese manufacturers must establish a separate Saudi vigilance reporting process and liaison with SFDA via the designated Authorized Representative; existing NMPA adverse event reporting does not cover Saudi post-market obligations. (4) Language: SFDA technical dossiers are submitted in English (or Arabic); NMPA submissions in Chinese must be translated. (5) PMS plans must explicitly address the Saudi market context.For informational reference only. Chinese manufacturers with NMPA-compliant clinical evaluation and ISO 14971/YY/T 0316 risk management files have a transferable foundation, but must reformat documentation for SFDA, translate to English, and establish Saudi-specific PMS and vigilance reporting arrangements. Manufacturers without a founding regulator approval must prepare a full clinical evidence package. Consult a qualified regulatory affairs professional for clinical evidence strategy and SFDA dossier preparation. | Saudi Food and Drug Authority (SFDA)2026-06-12 · unverified |
| Labelling — Arabic Language, Mandatory Label Elements, and UDI | In China, medical device labels must comply with the NMPA labelling requirements under the Administrative Measures for Medical Device Registration (NMPA Order No. 47, 2021) and the Medical Device Instructions for Use and Label Management Measures. Labels must be in Chinese (simplified). English may appear alongside Chinese. Mandatory elements include device name, registration number, manufacturer details, intended use, warnings, production/expiry date, lot/serial number, and storage conditions. China has implemented a phased UDI system since 2019, covering different device classes on a rolling schedule. Chinese UDI uses both barcode/QR code (AIDC) and human-readable text. China's label requirements are broadly similar in structure but are Chinese-language-centric, not Arabic.医疗器械说明书和标签管理规定 (NMPA — Instructions for Use and Label Management Measures) 医疗器械唯一标识系统规则 (NMPA UDI System Rules, 2019) GB/T 29791 — Labelling standards reference (verify applicability by device type) |
SFDA requires Arabic language on device labels. English is permitted alongside Arabic but does not substitute for it. Mandatory label elements include: device name and model/reference number, manufacturer name and address, intended use/indication, warnings and cautions in Arabic, storage and handling conditions, expiry date or manufacture date (as applicable), lot number or serial number, and sterility indicators (if applicable). Instructions for use must also be provided in Arabic. SFDA is implementing a Unique Device Identification (UDI) system in a phased rollout by device class and risk level — specific phase timelines and mandatory implementation dates should be verified with SFDA as the rollout is ongoing (verify current phase and compliance date). The UDI system requires a device identifier (UDI-DI) and production identifier (UDI-PI) to be carried on the label in both human-readable and automatic identification (AIDC/barcode) form.Royal Decree No. (M/54) 2021 — Law of Medical Devices, Saudi Arabia Medical Devices Interim Regulation (MDIR) 2019 — subordinate implementing regulation for labelling requirements SFDA Medical Device Labelling Guidelines SFDA UDI Implementation Guidance (phased — verify current phase) |
The structural labelling requirements are broadly similar, but four significant gaps exist for Chinese manufacturers: (1) Language: Arabic language is mandatory on Saudi labels; Chinese labels use simplified Chinese. Manufacturers must redesign labels to include Arabic text, including Arabic translations of warnings, indications, and instructions for use. Professional Arabic medical translation and regulatory review are required. (2) UDI phasing: China's UDI system and Saudi Arabia's SFDA UDI system are separate; UDI issuing agencies and system registrations are different. Manufacturers must register in the SFDA UDI system separately from China's UDI system (verify current SFDA UDI issuing agency requirements). (3) Registration number on label: SFDA labels reference the Saudi MDMA number, not the NMPA registration number. Labels must be updated post-MDMA approval. (4) No NMPA registration number: Saudi labels must not carry the NMPA registration number as a conformity indicator; this could mislead SFDA inspectors.For informational reference only. Arabic-language labelling is a firm requirement for the Saudi market and represents one of the most operationally visible changes for Chinese manufacturers. Label redesign, professional Arabic medical translation, and SFDA UDI system registration are all required steps distinct from Chinese market labelling. UDI phase deadlines should be verified directly with SFDA or a qualified regulatory affairs professional before finalizing label artwork. Manufacturers must also update labels post-MDMA approval to include the Saudi MDMA number. | Saudi Food and Drug Authority (SFDA)2026-06-12 · unverified |
| Market Authorization + Device Classification (MDMA / SFDA Classes) | In China, medical devices are regulated by the National Medical Products Administration (NMPA) under State Council Order No. 739 (2021). Devices are classified into three classes: Class I (lowest risk, filing/notification), Class II (registration with provincial NMPA), and Class III (registration with national NMPA). Registration requires a technical dossier, product standards (GB or YY/T), clinical evaluation, and QMS certification (YY/T 0287-2017 / ISO 13485 equivalent). NMPA registration is a domestic market authorization and is not directly recognized by SFDA for Saudi market access without a separate MDMA application.医疗器械监督管理条例 (State Council Order No. 739, 2021) 医疗器械注册与备案管理办法 (NMPA Order No. 47, 2021) YY/T 0287-2017 (ISO 13485:2016 equivalent) |
Medical devices placed on the Saudi Arabia market require a Medical Device Marketing Authorization (MDMA) from the Saudi Food and Drug Authority (SFDA). The primary legislation is Royal Decree No. (M/54) 2021 (Law of Medical Devices), with the Medical Devices Interim Regulation (MDIR) 2019 serving as subordinate implementing regulation. SFDA classifies devices into four risk classes: Class A (lowest risk), Class B, Class C, and Class D (highest risk). Class A devices require notification only; Classes B, C, and D require a full MDMA application including a technical dossier, ISO 13485 QMS certificate from an SFDA-recognized certification body, and clinical/safety evidence. SFDA may grant an expedited recognition pathway for devices already holding a valid marketing authorization from a founding regulator (US FDA, EU CE, Health Canada, TGA Australia, PMDA Japan) — such devices may be listed on the SFDA Recognition List and qualify for a streamlined MDMA process. The foreign manufacturer must appoint a Saudi-based Authorized Representative (AR) registered with SFDA for all MDMA applications.Royal Decree No. (M/54) 2021 — Law of Medical Devices, Saudi Arabia Medical Devices Interim Regulation (MDIR) 2019 — subordinate implementing regulation SFDA Medical Device Marketing Authorization (MDMA) Requirements SFDA Recognition List — Founding Regulators (US FDA, EU CE, Health Canada, TGA, PMDA) |
NMPA registration is not recognized by SFDA as a standalone pathway for Saudi market access. A separate MDMA application is required. Key gaps: (1) SFDA's four-class system (A/B/C/D) does not map directly to NMPA's three-class system (I/II/III) — reclassification analysis is required. (2) The MDMA technical dossier must satisfy SFDA-specific requirements; NMPA documentation may need supplementation or reformatting. (3) For devices already approved by a founding regulator (US FDA or EU CE), a recognition/fast-track pathway exists — Chinese manufacturers holding only NMPA registration do not qualify for this shortcut. (4) A Saudi-based Authorized Representative registered with SFDA is mandatory; China has no outbound equivalent requirement. (5) Class C/D devices may be subject to SFDA factory inspection.For informational reference only. Chinese manufacturers must obtain a separate SFDA MDMA before placing devices on the Saudi market. NMPA registration alone does not suffice. Manufacturers holding a valid US FDA or EU CE approval may explore the SFDA recognition/fast-track pathway. A qualified Saudi regulatory affairs professional and a locally registered Authorized Representative are required. Verify current SFDA classification rules and MDMA procedural requirements before filing. | Saudi Food and Drug Authority (SFDA)2026-06-12 · unverified |
| Quality Management System (ISO 13485 + SFDA QMS Requirements) | In China, medical device manufacturers must comply with the NMPA Quality Management System requirements under YY/T 0287-2017 (which is technically equivalent to ISO 13485:2016). Class II and III manufacturers must obtain QMS certification and pass NMPA GMP (Good Manufacturing Practice) inspections. YY/T 0287-2017 certificates are accepted for Chinese market registration but the certifying body must be recognized by NMPA/CNAS. NMPA GMP inspection results and YY/T 0287-2017 certificates are not directly accepted by SFDA; a separate ISO 13485:2016 certificate from an SFDA-recognized body is required for Saudi MDMA applications.YY/T 0287-2017 (ISO 13485:2016 equivalent — China) 医疗器械生产质量管理规范 (NMPA GMP for Medical Devices) 医疗器械监督管理条例 (State Council Order No. 739, 2021) |
SFDA requires a valid ISO 13485:2016 Quality Management System (QMS) certificate as a mandatory prerequisite for MDMA applications for Class B, C, and D medical devices. The certificate must be issued by a certification body recognized by SFDA. For Class C and D devices, SFDA may additionally conduct or require a factory inspection (on-site audit) of the manufacturing facility to verify QMS implementation. The QMS must cover design and development, production, post-market surveillance, and complaint handling activities relevant to the device being registered. Certificates issued by SFDA-unrecognized bodies are not accepted.ISO 13485:2016 — Medical devices: Quality management systems Royal Decree No. (M/54) 2021 — Law of Medical Devices, Saudi Arabia Medical Devices Interim Regulation (MDIR) 2019 — subordinate implementing regulation SFDA Medical Device Marketing Authorization Technical Dossier Requirements |
The core QMS standard (ISO 13485:2016) is the same between China (YY/T 0287-2017) and Saudi Arabia (SFDA requirement). However, three practical gaps exist: (1) SFDA requires the certificate to be issued by an SFDA-recognized certification body — CNAS-accredited Chinese certification bodies may not be on the SFDA recognized list; manufacturers must verify and may need to obtain a separate certificate from an SFDA-recognized international body. (2) SFDA may conduct a factory inspection for Class C/D devices; Chinese manufacturers must be prepared for SFDA auditors or their designated inspection agents. (3) The QMS scope must explicitly cover the product categories and activities being registered with SFDA; a scoping gap is common when the existing certificate was obtained for a different product range.For informational reference only. Chinese manufacturers with an existing YY/T 0287-2017 / ISO 13485:2016 certificate have a strong foundation, but must verify that the issuing body is recognized by SFDA and that the certificate scope covers the Saudi-registered product range. Class C/D manufacturers should prepare for potential factory inspection by SFDA. Consult a qualified regulatory affairs professional to confirm current SFDA-recognized certification body list before applying. | Saudi Food and Drug Authority (SFDA)2026-06-12 · unverified |
| Electromedical Safety (IEC 60601-1 + IEC 62304 Software) | China's national standard GB 9706.1-2020 is technically aligned with IEC 60601-1 Edition 3.1 and became mandatory from 2023-05-01 for new registrations. Earlier registrations under the old GB 9706.1-2007 (aligned to IEC 60601-1 Ed. 2) have been transitioning. Software as a medical device is addressed by YY/T 0664 (aligned to IEC 62304) and the NMPA SaMD technical guidance. EMC is covered by YY 9706.102-2021 (aligned to IEC 60601-1-2:2014). Test reports must be from CNAS-accredited laboratories or NMPA-designated test institutions. Since GB 9706.1-2020 is aligned (not identical) to IEC 60601-1 Ed. 3, existing CN test reports may cover most SFDA requirements but gaps related to local amendments or specific collateral standards should be verified.GB 9706.1-2020 (IEC 60601-1 Ed. 3.1 aligned — China) YY 9706.102-2021 (IEC 60601-1-2:2014 aligned — EMC) YY/T 0664 (IEC 62304 aligned — Software lifecycle) YY/T 0316 (ISO 14971 aligned — Risk management) |
SFDA's Essential Requirements for medical electrical equipment reference IEC 60601-1 Edition 3 and its collateral and particular standards. Test reports must be provided as part of the MDMA technical dossier. SFDA accepts test reports from laboratories accredited under the ILAC Mutual Recognition Arrangement (ILAC MRA). For devices already approved by a founding regulator (US FDA, EU CE, PMDA Japan, etc.), SFDA may accept test evidence submitted in the original founding regulator submission, reducing re-testing burden. For medical devices incorporating software (SaMD) or embedded software, IEC 62304 (medical device software lifecycle processes) compliance evidence is required. Collateral and particular standards applicable to the device type (e.g., IEC 60601-1-2 for EMC, IEC 60601-1-6 for usability, IEC 60601-1-11 for home healthcare) must also be addressed.Royal Decree No. (M/54) 2021 — Law of Medical Devices, Saudi Arabia Medical Devices Interim Regulation (MDIR) 2019 — subordinate implementing regulation IEC 60601-1:2005+AMD1:2012+AMD2:2020 (Ed. 3.2) — General requirements for basic safety and essential performance IEC 60601-1-2:2014+AMD1:2020 — EMC requirements IEC 60601-1-6:2010+AMD1:2013+AMD2:2020 — Usability IEC 60601-1-11:2015+AMD1:2020 — Home healthcare environment IEC 62304:2006+AMD1:2015 — Medical device software lifecycle processes SFDA Medical Devices Essential Requirements (MDS-REQ1) |
The underlying safety standards are closely aligned (both reference IEC 60601-1 Ed. 3), creating a favorable baseline. Key practical gaps: (1) SFDA requires test reports from ILAC MRA-accredited laboratories; CNAS is an ILAC MRA member, so CNAS-accredited lab reports are generally acceptable — manufacturers should confirm ILAC MRA membership is current. (2) GB 9706.1-2020 contains local Chinese amendments; any clause where the GB standard diverges from IEC 60601-1 Ed. 3 should be identified and documented in the SFDA dossier. (3) If the device was previously tested against IEC 60601-1 Ed. 2 (GB 9706.1-2007), re-testing to Ed. 3 will be required. (4) IEC 62304 software documentation must explicitly meet SFDA requirements — Chinese SaMD submissions formatted for NMPA may need restructuring. (5) Verify which specific collateral/particular standards SFDA requires for the device class and intended environment.For informational reference only. Chinese manufacturers complying with GB 9706.1-2020 and tested at CNAS-accredited (ILAC MRA member) laboratories are well-positioned for Saudi SFDA safety requirements. Key actions: confirm test lab ILAC MRA status, identify any GB-vs-IEC divergences in the technical file, and ensure IEC 62304 software documentation is structured to SFDA expectations. Consult a qualified regulatory affairs professional for device-specific gap analysis. | Saudi Food and Drug Authority (SFDA)2026-06-12 · unverified |
E-E-A-T
Named editorial review
Pending named reviewer
Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.
Editorial controlsRows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.
SOURCES
Official-source register.
- Saudi Food and Drug Authority (SFDA) · accessed 2026-06-12 · unverified · used in 6 rows